公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2018 | Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6) | Wu Y.-L; Hirsh V; Sequist L.V; Hu C.-P; Feng J; Lu S; Huang Y; Schuler M; Mok T; Yamamoto N; O’Byrne K; Geater S.L; Zhou C; Massey D; Märten A; Lungershausen J; CHIH-HSIN YANG | Patient | 20 | 17 | |
2016 | Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: Post hoc analyses of the randomized LUX-Lung 3 and 6 trials | CHIH-HSIN YANG ; Sequist L.V; Zhou C; Schuler M; Geater S.L; Mok T; Hu C.-P; Yamamoto N; Feng J; O'Byrne K; Lu S; Hirsh V; Huang Y; Sebastian M; Okamoto I; Dickgreber N; Shah R; Märten A; Massey D; Wind S; Wu Y.-L. | Annals of Oncology | 152 | 142 | |
2013 | Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations | Sequist L.V; CHIH-HSIN YANG ; Yamamoto N; O'Byrne K; Hirsh V; Mok T; Geater S.L; Orlov S; Tsai C.-M; Boyer M; Su W.-C; Bennouna J; Kato T; Gorbunova V; Lee K.H; Shah R; Massey D; Zazulina V; Shahidi M; Schuler M. | Journal of Clinical Oncology | 2727 | 2366 | |
2016 | A randomized phase 2 study comparing the combination of ficlatuzumab and gefitinib with gefitinib alone in asian patients with advanced stage pulmonary adenocarcinoma | Mok T.S.K; Geater S.L; Su W.-C; Tan E.-H; CHIH-HSIN YANG ; Chang G.-C; Han M; Komarnitsky P; Payumo F; Garrus J.E; Close S; Park K. | Journal of Thoracic Oncology | 44 | 41 |